Evaluation of sequencing of HCV core/E1, NS5A and NS5B as a genotype predictive tool in comparison with commercial assays targeting 5'UTR

Journal of Clinical Virology

Volumn 66, Issue , 2015, Pages 56-59

  McCormick, Adele L ^a   Macartney, Malcolm J ^a   Abdi Abshir, Ikran ^a   Labbett, Wendy ^a   Smith, Colette ^b   Irish, Dianne ^a   Webster, Daniel P ^a   Haque, Tanzina ^a  

^a ROYAL FREE LONDON NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

DNA sequencing; Genotyping; Hepatitis C virus; LiPA; RealTime PCR; Subtyping

Indexed keywords

GLYCOPROTEIN E1; NONSTRUCTURAL PROTEIN 5A; NONSTRUCTURAL PROTEIN 5B; 5' UNTRANSLATED REGION; CORE PROTEIN; NS-5 PROTEIN, HEPATITIS C VIRUS; NUCLEOCAPSID PROTEIN, HEPATITIS C VIRUS; VIRUS PROTEIN;

5' UNTRANSLATED REGION; ARTICLE; ASSAY; CLINICAL ARTICLE; GENE SEQUENCE; GENOMICS; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MIXED INFECTION; PRIORITY JOURNAL; CLASSIFICATION; COMPARATIVE STUDY; DNA SEQUENCE; EVALUATION STUDY; GENETICS; GENOTYPING TECHNIQUE; HEPACIVIRUS; PROCEDURES; REAL TIME POLYMERASE CHAIN REACTION;

5' UNTRANSLATED REGIONS; GENOTYPE; GENOTYPING TECHNIQUES; HEPACIVIRUS; HUMANS; REAL-TIME POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS, DNA; VIRAL CORE PROTEINS; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84926678842     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2015.03.006     Document Type: Article

References (18)

1. Messina J.P., Humphreys I., Flaxman A., Brown A., Cooke G.S., Pybus O.G., Barnes E. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology 2015, 61(1):77-87. 10.1002/hep.27259.
2. Benedet M., Adachi D., Wong A., Wong S., Pabbaraju K., Tellier R., Tang J.W. The need for a sequencing-based assay to supplement Abbott m2000 RealTime HCV Genotype II assay: a 1 year analysis. J. Clin. Virol. 2014, 60(3):301-304. 10.1016/j.jcv.2014.04.005.
3. González V., Gomes-Fernandes M., Basuñana E., Casanovas S., Saludes V., Jordan-Lluch E., Matas L., Ausina V., Martró E. Accuracy of a commercially available assay for HCV genotyping and subtyping in the clinical practice. J. Clin. Virol. 2013, 58(1):249-253. 10.1016/j.jcv.2013.05.005.
4. Pollicita M., Cento V., Paba P., Perno C.F., Ciotti M. Nucleotide polymorphisms in the 5'-UTR region of HCV can affect the ability of two widely used assays to assign an HCV genotype. J. Virol. Methods 2013, 193(1):205-208. 10.1016/j.jviromet.2013.06.002.
5. Davalieva K., Kiprijanovska S., Plaseska-Karanfilska D. Fast, reliable and low cost user-developed protocol for detection, quantification and genotyping of hepatitis C virus. J. Virol. Methods 2014, 196:104-112. 10.1016/j.jviromet.2013.11.002.
6. Fakhr A.E., Pourkarim M.R., Maes P., Atta A.H., Marei A., Azab M., Van Ranst A. Hepatitis C. virus NS5B sequence-based genotyping analysis of patients from the Sharkia Governorate. Egypt. Hepat. Mon. 2013, 13(12). 10.5812/hepatmon.12706.
7. Simmonds P. Genetic diversity and evolution of hepatitis C virus- 15 years on. J. Gen. Virol. 2004, 85(11):3173-3188.
8. Nakatani S.M., Santos C.A., Riediger I.N., Krieger M.A., Duarte C.A., do Carmo Debur M., Carrilho F.J., Ono S.K. Comparative performance evaluation of hepatitis C virus genotyping based on the 5' untranslated region versus partial sequencing of the NS5B region of Brazilian patients with chronic hepatitis C. Virol. J. 2011, 8:459. 10.1186/1743-422X-8-459.
9. McCormick A.L., Wang L., Garcia-Diaz A., Macartney M.J., Webster D.P., Haque T. Prevalence of baseline polymorphisms for potential resistance to NS5A inhibitors in drug-naïve individuals infected with hepatitis C genotypes 1-4. Antiviral Ther. 2015, 20(1):81-85. 10.3851/IMP2763.
10. Avó A.P., Água-Doce I., Andrade A., P'adua E. Hepatitis C. virus subtyping based on sequencing of the C/E1 and NS5B genomic regions in comparison to a commercially available line probe assay. J. Med. Virol. 2013, 85(5):815-822. 10.1002/jmv.23545.
11. Thompson W.D., Walter S.D. Kappa and the concept of independent errors. J. Clin. Epidemiol. 1988, 41:969-970.
12. Chevaliez S., Bouvier-Alias M., Brillet R., Pawlotsky J.M. Hepatitis C. virus (HCV) genotype 1 subtype identification in new HCV drug development and future clinical practice. PLoS One 2009, 4(12). 10.1371/journalpone.0008209.
13. Cai Q., Zhao Z., Liu Y., Shao X., Gao Z. Comparison of three different HCV genotyping methods: core,NS5B sequence analysis and line probe assay. Int. J. Mol. Med. 2013, 31(2):347-352. 10.3892/ijmm.2012.1209.
14. Simmonds P., Bukh J., Combet C., Deléage G., Enomoto N., Feinstone S., Halfon P., Inchauspé G., et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 2005, 42(4):962-973.
15. Murphy D.G., Willems B., Deschênes M., Hilzenrat N., Mousseau R., Sabbah S. Use of sequence analysis of the NS5B region for routine genotyping of hepatitis C virus with reference to C/E1 and 5ê untranslated region sequences. J. Clin. Microbiol. 2007, 45(4):1102-1112.
16. Lau J.Y., Mizokami M., Kolberg J.A., Davies G.L., Prescott L.E., Ohno T. Application of six hepatitis C virus genotyping systems to sera from chronic hepatitis C patients in the United States. J. Infect. Dis. 1995, 171:281-289.
17. Pawlotsky J.M. Therapeutic implications of hepatitis C virus resistance to antiviral drugs. Ther. Adv. Gastroenterol. 2009, 2:205-219.
18. Wyles D., Pockros P., Zhu Y., Yang J.C., Pang P.S., McHutchison J.G., Flamm S., Lawitz E. Retreatment of patients who failed prior Sofosbuvir-based regimens with all oral fixed-dose combination Ledipasvir/Sofosbuvir plus Ribavirin for 12 weeks. 65th AASLD 2014, Abstract 235.